Apathy clinical trials

Explore recruiting apathy clinical trials.

Recruiting apathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Apathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

In vivo involvement of the cholinergic and dopaminergic systems in the pathophysiology of apathy. ADACHOL.

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

INITIATE-LECIG: Intestinal levodopa + entacapone therapy (Lecigon®) to counteract dopaminergic desensitization and neuropsychiatric complications in Parkinson’s disease

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, single-centre, randomised, double-blind, placebo-controlled, phase I, First-In-Human (FIH) trial evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.

Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and Apathy

Bulgaria, Poland, Spain, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

ASSESSMENT OF THE BRAIN DEPOSIT OF TAU 4R DETECTED BY BRAIN PET WITH 18F-PI2620 IN PROGRESSIVE SUPRANUCLEAR PALSY COMPARED TO CONTROLS WITHOUT NEURODEGENERATIVE TAUOPATHY 4R: A CLINICAL TRIAL

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

Apathy trials by city

Apathy in Toronto Apathy in Vancouver Apathy in Montreal Apathy in Calgary Apathy in Edmonton Apathy in Ottawa Apathy in Winnipeg Apathy in Quebec City Apathy in Hamilton Apathy in Kitchener Apathy in London Apathy in Halifax Apathy in New York Apathy in Los Angeles Apathy in Chicago Apathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease